The aim of this work was to analyze the presence of somatic variants in TP53, BRCA1, and BRCA2 in EOC by massive parallel sequencing, estimating the proportion of these variants in tumor samples and their association with progression‐free survival (PFS) and overall survival (OS). The gene discussed is BRCA2; the disease is neoplasm.